

Factsheet H1/2015



COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 220,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	H1/2015	H1/2014	Change	2014
Sales and Earnings				
Sales	13,429	10,733	25%	23,231
EBIT ¹	1,822	1,403	30%	3,158
Net income (before special items) ²	642	487	32%	1,086
Earnings per ord. share in € (before special items) ²	1.18	0.90	31%	2.01
Balance sheet and cash flow				
Total assets	42,271		6% ⁶	39,897
Non-current assets	31,758		6% ⁶	29,869
Equity ³	16,909		9% ⁶	15,483
Equity ratio ³	40%		--	39%
Net debt/EBITDA ⁴	3.19		--	3.41
Investments ⁵	805	1,738	-54%	3,795
Operating cash flow	1,251	750	67%	2,585
Operating cash flow in % of sales	9.3%	7.0%	--	11.1%
Profitability				
EBIT margin ¹	13.6%	13.1%	--	13.6%
Return on equity after taxes (ROE) ^{1,2}	12.2%		--	11.6%
Return on operating assets (ROOA) ⁴	9.6%		--	9.1%
Return on invested capital (ROIC) ⁴	7.8%		--	7.5%
Employees	220,339		2% ⁶	216,275

¹ Before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA

³ Including noncontrolling interest


⁴ Pro forma acquisitions, before special items

⁵ Investments in property, plant and equipment, and intangible assets, acquisitions

⁶ Change compared to December 31, 2014

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.



¹ As of June 30, 2015


BUSINESS SEGMENTS

€ in millions		H1/2015	H1/2014	Change	2014
FRESENIUS MEDICAL CARE	Sales	7,312	5,399	35%	11,917
	EBIT	942	731	29%	1,697
FRESENIUS KABI	Sales	2,932	2,466	19%	5,146
	EBIT ¹	571	411	39%	873
FRESENIUS HELIOS	Sales	2,774	2,521	10%	5,244
	EBIT ¹	307	250	23%	553
FRESENIUS VAMED	Sales	463	398	16%	1,042
	EBIT	16	15	7%	59


¹ Before special items

- ▶ **Fresenius Medical Care** is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure. As of June 30, 2015, Fresenius Medical Care was treating 289,610 patients in 3,421 dialysis clinics.
- ▶ **Fresenius Kabi** offers infusion therapies, intravenously administered generic drugs and clinical nutrition for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.
- ▶ **Fresenius Helios** is Germany's largest hospital operator. HELIOS operates 111 hospitals, thereof 87 acute care clinics (including seven maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal) and 24 post-acute care clinics. HELIOS treats approximately 4.5 million patients per year, thereof 1.2 million inpatients, and operates more than 34,000 beds.
- ▶ **Fresenius Vamed** manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.

SALES BY REGION




SALES BY BUSINESS SEGMENT




FRESENIUS SHARE/ADR

	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (June 30, 2015)	543,478,807
Market capitalization (June 30, 2015)	€31.3 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX



DEVELOPMENT SHARE DIVIDENDS IN €¹



¹ 2005 – 2013 adjusted for share split

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Mats Henriksson, Dr. Francesco De Meo, Dr. Jürgen Götz, Rice Powell, Stephan Sturm, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

FRESENIUS GROUP'S SENIOR NOTES

Issuer	ISIN	Volume in million	Coupon	Maturity
Fresenius Finance B. V.	XS1013954646	€300	2.375%	2019
Fresenius Finance B. V.	XS0759200321	€500	4.25%	2019
Fresenius Finance B. V.	XS0873432511	€500	2.875%	2020
Fresenius Finance B. V.	XS1013955379	€450	3.00%	2021
Fresenius Finance B. V.	XS1026109204	€450	4.00%	2024
Fresenius US Finance II, Inc.	USU31436AD72	US\$500	9.00%	2015
Fresenius US Finance II, Inc.	XS0390398344	€275	8.75%	2015
Fresenius US Finance II, Inc.	USU31436AG04	US\$300	4.250%	2021
Convertible bonds				
Fresenius SE & Co. KGaA	DE000A1YC3T6	€500	0.00%	2019

¹ Repaid as of July 15, 2015
Bonds of Fresenius Medical Care can be found under [www.fmc-ag.com/Investor Relations\Credit Relations](http://www.fmc-ag.com/Investor%20Relations/Credit%20Relations).

SHARE PERFORMANCE¹

1 month	-0.7%
1 st quarter	+3.5%
1 st half	+33.3%
1 year	+58.5%
5 years	+217.2%
10 years	+478.6%

¹ Effective date/closing price: June 30, 2015

GROUP OUTLOOK 2015

	Targets 2015
Sales, growth (in constant currency)	8% – 10%
Net income ¹ , growth (in constant currency)	18% – 21%
Capital expenditure	~6% of group sales

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before integration costs (–€10 million before tax for hospitals acquired from Rhön-Klinikum AG), before costs for the efficiency program at Fresenius Kabi (–€100 million before tax) and before disposal gains from the divestment of two HELIOS hospitals (€34 million before tax); 2014 before special items

For the outlook of the business segments please see the Investor News of July 30, 2015.

FINANCIAL CALENDAR

	Dates
Report on 3 rd quarter 2015	October 29, 2015
Annual General Meeting, Frankfurt/Main	May 13, 2016

Please note that these dates could be subject to modifications.

CONTACT

Fresenius SE & Co. KGaA

Eise-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
e-mail: ir-fre@fresenius.com
Internet: www.fresenius.com

Markus Georgi
Senior Vice President
Investor Relations

Telephone: ++49 61 72 6 08-24 85
Telefax: ++49 61 72 6 08-24 88

Leslie Ittgen
Vice President
Investor Relations

Telephone: ++49 61 72 6 08-44 78
Telefax: ++49 61 72 6 08-24 88